EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSRFEG00010006472
Gene Symbol: CACNB2
1 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSRFEG00010008761
Gene Symbol: CACNB3
1 Cross references
275 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSRFEG00010001762
Gene Symbol: CACNB4
1 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1

Ensembl ID : ENSRFEG00010005775
Gene Symbol: CACNG1
1 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSRFEG00010004070
Gene Symbol: CACNG2
1 Cross references
259 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 3

Ensembl ID : ENSRFEG00010015158
Gene Symbol: CACNG3
1 Cross references
256 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSRFEG00010005798
Gene Symbol: CACNG4
1 Cross references
256 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSRFEG00010005828
Gene Symbol: CACNG5
1 Cross references
249 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSRFEG00010008832
Gene Symbol: CACNG6
1 Cross references
248 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSRFEG00010008794
Gene Symbol: CACNG8
1 Cross references
238 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSRFEG00010012402
Gene Symbol: CACNA1A
1 Cross references
283 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSRFEG00010011470
Gene Symbol: CACNA1B
1 Cross references
287 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).